• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Waldencast plc - Class A Ordinary Share (NQ:WALD)

    1.020 UNCHANGED
    Streaming Delayed Price Updated: 4:15 PM EDT, Mar 26, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2
    Open 1.020
    Bid (Size) 0.4100 (100)
    Ask (Size) 1.600 (200)
    Prev. Close 1.020
    Today's Range 1.020 - 1.020
    52wk Range 1.000 - 3.220
    Shares Outstanding 9,342,874
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Obagi Medical Introduces NU-GEN™ Cellular Renewal Serum Designed to Visibly Rewind Skin’s Age and Restore Visible Youthfulness
    The clinically proven formula pairs NAD+ with its precursors to replenish skin cells and address nine signs of skin aging for healthier, more resilient-looking skin 
    From Waldencast plc
    Via GlobeNewswire
    News headline image
    Obagi Medical and ProMD Announce Collaboration in the ALOHA Program to Advance Clinical Evidence with Obagi® saypha® MagIQ™
    ProMD’s multi-location physician led network will participate in Obagi’s ALOHA Program as part of a structured evaluation of MagIQ and integrated skincare protocols to providers across multiple states 
    From Waldencast plc
    Via GlobeNewswire

    Performance

    YTD
    -40.4%
    -40.4%
    1 Month
    -42.0%
    -42.0%
    3 Month
    -48.7%
    -48.7%
    6 Month
    -49.3%
    -49.3%
    1 Year
    -67.3%
    -67.3%

    More News

    Read More
    News headline image
    Waldencast Reports Q4 2025 and FY 2025 Financial Results
    From Waldencast plc
    Via GlobeNewswire
    News headline image
    Waldencast plc Announces Fourth Quarter and Fiscal Year 2025 Earnings Date
    From Waldencast plc
    Via GlobeNewswire
    News headline image
    Obagi Medical and Schweiger Dermatology Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
    From Waldencast plc
    Via GlobeNewswire
    News headline image
    Obagi Medical and It’s a Secret Med Spa Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
    From Waldencast plc
    Via GlobeNewswire
    News headline image
    Obagi Medical and Aesthetic Record Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
    From Waldencast plc
    Via GlobeNewswire
    News headline image
    Obagi Medical and DermFx Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
    From Waldencast plc
    Via GlobeNewswire
    News headline image
    Obagi Medical and Moxie Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
    From Waldencast plc
    Via GlobeNewswire
    News headline image
    Obagi Medical Introduces New Lip Therapy Protocol Designed to Resurface, Replenish, and Protect
    From Waldencast plc
    Via GlobeNewswire
    News headline image
    Obagi Medical and VIO Med Spa Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
    From Waldencast plc
    Via GlobeNewswire
    News headline image
    Obagi Medical and Next Health Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
    From Waldencast plc
    Via GlobeNewswire
    News headline image
    UPDATE - Obagi Medical and Alpha Aesthetic Partners Announce Their Collaboration in the ALOHA Program to Drive Real-World Evidence with Obagi® saypha® MagIQ™
    From Waldencast plc
    Via GlobeNewswire
    News headline image
    Obagi Medical and Alpha Aesthetic Partners Announce Their Collaboration in the ALOHA Program to Drive Real-World Evidence with Obagi® saypha® MagIQ™
    From Waldencast plc
    Via GlobeNewswire
    News headline image
    CORRECTION – Obagi Medical and Platinum Dermatology Partners Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
    From Waldencast plc
    Via GlobeNewswire
    News headline image
    Obagi Medical and Platinum Dermatology Partners Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
    From Waldencast plc
    Via GlobeNewswire
    News headline image
    Obagi Medical Unveils ALOHA Program to Launch Obagi® saypha® MagIQ™ – Pioneering the Largest Real-World Evaluation of a New Hyaluronic Acid Filler
    From Waldencast plc
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Waldencast plc - WALD
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Waldencast plc - WALD
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Waldencast Announces Q2 2025 Results and Provides Q3 2025 Trading Update
    From Waldencast plc
    Via GlobeNewswire
    News headline image
    Obagi Medical Shares New Clinical Data on Obagi Hyaluronic Acid Injectables and Nu-Cil Scalp Serum at the 2025 American Society for Dermatologic Surgery Annual Meeting
    From Waldencast plc
    Via GlobeNewswire
    News headline image
    Waldencast plc strengthens balance sheet position with the announcement of a trademark sale for Japan and refinancing of its credit facilities
    From Waldencast plc
    Via GlobeNewswire
    News headline image
    Waldencast plc Provides Information Regarding Upcoming Earnings Release Dates
    From Waldencast plc
    Via GlobeNewswire
    News headline image
    Obagi Medical Launches Nu-Cil® BioStim™ Scalp Serum
    From Waldencast plc
    Via GlobeNewswire
    News headline image
    Waldencast Announces FDA Approval of Obagi® saypha® MagIQ™ Injectable Hyaluronic Acid Gel Under the Obagi Medical Brand
    From Waldencast plc
    Via GlobeNewswire

    Frequently Asked Questions

    Is Waldencast plc - Class A Ordinary Share publicly traded?
    Yes, Waldencast plc - Class A Ordinary Share is publicly traded.
    What exchange does Waldencast plc - Class A Ordinary Share trade on?
    Waldencast plc - Class A Ordinary Share trades on the Nasdaq Stock Market
    What is the ticker symbol for Waldencast plc - Class A Ordinary Share?
    The ticker symbol for Waldencast plc - Class A Ordinary Share is WALD on the Nasdaq Stock Market
    What is the current price of Waldencast plc - Class A Ordinary Share?
    The current price of Waldencast plc - Class A Ordinary Share is 1.020
    When was Waldencast plc - Class A Ordinary Share last traded?
    The last trade of Waldencast plc - Class A Ordinary Share was at 03/26/26 04:15 PM ET
    What is the market capitalization of Waldencast plc - Class A Ordinary Share?
    The market capitalization of Waldencast plc - Class A Ordinary Share is 9.53M
    How many shares of Waldencast plc - Class A Ordinary Share are outstanding?
    Waldencast plc - Class A Ordinary Share has 10M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.